Table 3.
Completed and ongoing clinical trials of anti-telomerase vaccines: current status
| Identifier code/phase | Indication | Objective | Start/completion date | Results | Sponsor/reference |
|---|---|---|---|---|---|
| NCT00510133/GRNVAC1 phase II | Acute myelogenous leukemia | Efficacy | July 2007/August 2014 | GRNVAC1 was found to be safe and well tolerated. Positive immune responses in 55 % of patients. Toxicity: thrombocytopenia. |
Asterias Biotherapeutics (http://asteriasbiotherapeutics.com/pipeline/ast-vac1/) |
| NCT01579188/GV1001 phase III | Non-small-cell lung cancer | Efficacy | May 2012/May 2016 | Ongoing. | Kael-GemVax |
| NCT00425360/GV1001 phase III | Metastatic pancreatic cancer | Efficacy in combination with chemotherapy | September 2006/ March 2013 |
Adding GV1001 vaccination to chemotherapy did not improve overall survival. | [108] |
| NCT01935154/Vx001 phase II | Non-small-cell lung cancer | Efficacy | August 2012/ December 2016 |
Active. | Vaxon Biotech (http://www.clinicaltrials.gov) |